| Literature DB >> 30805305 |
Robert-Christopher Karl-Richard Eschke1, Amit Lampit2,3, Alexander Schenk1, Florian Javelle1, Karen Steindorf4, Patrick Diel1, Wilhelm Bloch1, Philipp Zimmer1,4.
Abstract
Background: Physical exercise is suspected to reduce cancer risk and mortality. So far, little is known about the underlying mechanisms. Although limited, murine models represent a promising attempt in order to gain knowledge in this field. Objective: A systematic review and meta-analysis examining various treatment protocols was conducted in order to determine the impact of exercise on tumor growth in rodents.Entities:
Keywords: cancer; physical exercise; rodent models; training initiation; tumor growth
Year: 2019 PMID: 30805305 PMCID: PMC6370688 DOI: 10.3389/fonc.2019.00035
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Electronic data base search strategy.
| Exercise | Physical activity, running, swimming | Wheel running, treadmill running, high intensity, low intensity, moderate intensity |
| Neoplasm | Breast cancer, mammary tumor, liver cancer, prostate cancer, lymphocytes, malignancy | Walker 256, morris hepatoma, lewis lung carcinoma, nitrosomethylurea |
| Rodentia | Mice, rats, murines | Rodents, animals, animal testing, animal models |
| Tumor burden | Tumor volume, tumor weight, tumor growth | Tumor weight per animal |
| Human | Human trials | – |
| Search string: | ||
| ((((((((((((exercise) OR physical activity) OR running) OR swimming) OR wheel running) OR treadmill running) OR high intensity) OR low intensity) OR moderate intensity) AND (((((((((((neoplasm) OR breast cancer) OR mammary tumor) OR liver cancer) OR prostate cancer) OR lymphocytes) OR malignancy) OR walker 256) OR morris hepatoma) OR lewis lung carcinoma) OR nitrosomethylurea) AND (((((((rodentia) OR mice) OR rats) OR murines) OR rodents) OR animals) OR animal testing) OR animal models) NOT Human) OR human trials) AND (((((tumor burden) OR tumor volume) OR tumor weight) OR tumor growth) OR tumor weight per animal) | ||
Figure 1Study selection flow chart according to the PRISMA guidelines.
OHAT Risk of Bias heat map for randomized controlled trials investigating tumor size in exercised rodents.
| Selection bias | Q1a: Was the administered dose of exposure level adequately randomized? | – | + | + | + | – | + | – | |||||||||||||
| Q1b: Was allocation to study groups adequately concealed? | – | – | – | – | – | – | – | ||||||||||||||
| Performance Bias | Q2a: Were experimental conditions identical across study groups? | + | + | + | ++ | + | ++ | ++ | |||||||||||||
| Q2b: Were the research personnel and human subjects blinded to the study group? | – – | – | – | – | – | – | – | ||||||||||||||
| Attrition/Exclusion Bias | Q3: Were outcome data complete without attrition or exclusion from analysis? | + | ++ | ++ | ++ | – | ++ | – | |||||||||||||
| Detection bias | Q4a: Can we be confident in the exposure characterization? | ++ | ++ | ++ | ++ | ++ | ++ | ++ | |||||||||||||
| Q4b: Can we be confident in the outcome assessment? | – | – | – | – | – | – | – | ||||||||||||||
| Selective Reporting Bias? | Q5: Were all measured outcomes reported? | + | ++ | ++ | ++ | ++ | ++ | ++ | |||||||||||||
| – | + | + | + | – | + | + | + | ||||||||||||||
| Other Bias | Were statistical methods appropriate? | ||||||||||||||||||||
| Did researchers adhere to the study protocol? | |||||||||||||||||||||
| Did the study design or analysis account for important confounding variables in experimental studies? | |||||||||||||||||||||
Based on the work of Wikoff et al. (.
Publication bias assessment of the Egger's regression intercepts calculation.
| Intercept | −1.96675 |
| Standard error | 1.27892 |
| 95% CI lower limit(2-tailed) | −4.66504 |
| 95% CI upper limit(2-tailed) | 0.73154 |
| 1.53782 | |
| Degrees of freedom | 17 |
| 0.07125 | |
| 0.14250 | |
Figure 2Funnel Plot of standard error against hedges' g after Duval and Tweedie's trim and fill.
Figure 3Sensitivity analysis “one study removed” function, of the “comprehensive meta-analysis” program.
Summary of studies included in the meta-analysis.
| 1 | Almeida et al. ( | 8 | 11 | Male Swiss mice (49 days) | Subcutaneous inoculation of 2 × 106 Ehrlich tumor cells in 0.05 ml in the dorsal area of animals | Swimming with progressive loads | 60 min/day; 5 days/weeks | 4 weeks before and 2 weeks after inoculation | Tumor weight [mg] per animal [g] | 0.180 | 0.050 | 0.550 | 0.100 | ↓ |
| Almeida et al. ( | 8 | 11 | Male Swiss mice (49 days) | Subcutaneous inoculation of 2 × 106 Ehrlich tumor cells in 0.05 ml in the dorsal area of animals | Swimming with progressive loads | 60 min/d; 5 days/weeks | 4 weeks before and 2 weeks after inoculation | Tumor size in [mm3] | 0.110 | 0.030 | 0.480 | 0.100 | ↓ | |
| 2 | Aveseh et al. ( | 9 | 10 | Female BALB/c mice (35 days) | Subcutaneous injection of 1.2 × 106 MC4-L2 cells into right dorsal mammary fat pad | Treadmill running | 55 min/d; 7 days/weeks | 4 weeks after inoculation for 7 weeks | Tumor weight [mg] per animal [g] | 28.500 | 0.619 | 31.800 | 0.298 | ↓ |
| 3 | Bacurau et al. ( | 24 | 24 | Male Wistar rats (56 days) | Subcutaneous inoculation of 1 ml sterile suspension of 2 × 107 Walker 256 tumor cells in right flank | Treadmill running | 30 min/d; 5 days/weeks | 8 weeks before and 2 weeks after inoculation | Tumor weight [mg] per animal [g] | 22.200 | 1.800 | 38.800 | 3.200 | ↓ |
| 4 | de Lima et al. ( | 18 | 18 | Male Wistar rats (60 days) | Subcutaneous inoculation of 1 ml Walker 256 tumor cells 2 × 107 cells/ml in right flank | Jumping in water | 5 min/d; 4 day/weeks | 6 weeks before inoculation 2 weeks after | Tumor weight [g] | 16.50 | 1.600 | 25.100 | 2.000 | ↓ |
| 5 | de Lima et al. ( | 18 | 18 | Male Wistar rats (70 days) | Subcutaneous inoculation of 1 ml Walker 256 tumor cells 2 × 107 cells/ml suspension in right flank | Jumping in water | 5 min/d; 4 days/weeks | 6 weeks before inoculation 2 weeks after | Tumor weight [g] | 17.03 | 1.190 | 24.300 | 1.350 | ↓ |
| 6 | Faustino-Rocha et al. ( | 15 | 15 | Female Sprague-Dawley rats (49 days) | Intraperitoneal administration of 50 mg/kg body weight of N-methyl-N-nitrosourea | Treadmill running | 60 min/d; 5 days/weeks | Right after inoculation for 35 weeks | Tumor size in [mm3] | 7870.00 | 2820.000 | 4880.000 | 1930.000 | ↗ |
| Faustino-Rocha et al. ( | 15 | 15 | Female Sprague-Dawley rats (49 days) | Intraperitoneal administration of 50 mg/kg body weight of N-methyl-N-nitrosourea | Treadmill running | 60 min/d; 5 days/weeks | Right after inoculation for 35 weeks | Tumor weight [g] | 8.310 | 2.820 | 5.150 | 2.040 | ↗ | |
| 7 | Gueritat et al. ( | 10 | 10 | Male Copenhagen rats (70–84d) | Subcutaneous abdominal tumor fragment implant (20 mg), Dunning AT1 | Treadmill running | 60 min/d; 5 days/weeks | 15 days post-implantation for 4 weeks | Tumor size in [mm3] | 3610.00 | 2280.000 | 6050.000 | 2040.000 | ↙ |
| 8 | Salomão et al. ( | 8 | 9 | Male Wistar rats (21 days) | Subcutaneous inoculation of 1 ml Walker 256 tumor cells 0,25 × 106 cells/ml in right flank | Light swim training | 45 min/d; 5 days/weeks | 60 days before and 21 days after inoculation | Tumor weight [g] | 40.00 | 5.500 | 57.500 | 5.800 | ↓ |
| 9 | Shewchuk et al. ( | 16 | 11 | Female Sprague-Dawley rats (59 days) | Subcutaneous injection of 20 μl Morris Hepatoma 7777 tumor tissue | Swim training | 180 min/d; 6 days/weeks | Right after inoculation for 14 days | Tumor weight [g] | 8.800 | 0.500 | 9.400 | 1.100 | ↙ |
| 10 | Steiner et al. ( | 12 | 15 | Female C3(1)/SV40Tag mice (28 days) | Spontaneous tumor detection | Voluntary wheel running | N.A. | Continuous access to running wheels | Tumor size in [mm3] | 3581.60 | 705.600 | 4190.800 | 797.900 | ↙ |
| 11 | Tsai et al. ( | 10 | 9 | Male C57BL/6 Mice (56 days) | Subcutaneous inoculation with 5 × 105 Lewis lung carcinoma cells | Treadmill running | 60 min/d; 5 days/weeks | 1 weeks after inoculation for 4 weeks | Tumor weight [g] | 4.640 | 1.120 | 3.700 | 0.830 | ↗ |
| 12 | Westerlind et al. ( | 46 | 51 | Female Sprague-Dawley rats (20 days) | Intraperitoneal administration of 50 mg/kg body weight of 1-methyl 1-nitrosourea (MNU) | Treadmill running | 30 min/d; 5 days/weeks | Right after inoculation 2,4,6, or 8 f weeks | Tumor weight [mg] per animal [g] | 7.270 | 2.400 | 10.020 | 2.650 | ↙ |
| 13 | Westerlind et al. ( | 32 | 57 | Female Sprague-Dawley rats (20 days) | Intraperitoneal administration of 25 mg/kg body weight of 1-methyl 1-nitrosourea (MNU) | Treadmill running | 30 min/d; 5 days/weeks | Right after inoculation for 2,4,6, or 8 weeks | Tumor weight [mg] per animal [g] | 1.173 | 0.267 | 2.580 | 0.519 | ↙ |
| 14 | Whittal and Parkhouse ( | 26 | 29 | Female Sprague-Dawley rats (21 days) | Intraperitoneal administration of 50 mg/kg body weight of nitrosomethylurea (NMU) | Treadmill running | 60 min/d; 5 days/weeks | 39 days before inoculation | Tumor weight [g] | 2.100 | 0.650 | 2.600 | 0.670 | ↙ |
| 15 | Whittal-Strange et al. ( | 40 | 40 | Female Sprague-Dawley rats (21 days) | Intraperitoneal administration of 37.5 mg/kg body weight of nitrosomethylurea (NMU) | Treadmill running | 60 min/d; 5 days/weeks | 39 days before inoculation | Tumor weight [g] | 3.200 | 0.740 | 1.200 | 0.340 | ↑ |
| 16 | Yan and Demars ( | 30 | 30 | Male C57BL/6 mice (21 days) | Subcutaneous injection of Lewis Lung Carcinoma (2.5 x 105/50 μl/mouse) in the lower dorsal region | Voluntary wheel running | N.A. | 9 weeks before inoculation and cont. for 2 weeks after removal | Tumor size in [mm3] | 0.010 | 0.001 | 0.012 | 0.001 | ↙ |
| 17 | Yan and Demars ( | 30 | 28 | Male C57BL/6 mice (21 days) | Intravenous injection of B16BL/6 cells (0.75 × 105/200 μl/mouse) through lateral tail vein | Voluntary wheel running | N.A. | 9 weeks before inoculation and cont. for 2 weeks | Tumor size in [mm3] | 2.136 | 0.171 | 1.928 | 0.138 | ↗ |
| 18 | Zhang et al. ( | 6 | 6 | Male C57BL/6 Mice (42 days) | Subcutaneous injection of 5 × 106 Hepa1-6 cells +3 × 106 Hepa1-6-green fluorescent protein cells | Voluntary swimming | 8 min/day;5 days/weeks | 3 weeks before and 6 weeks after inoculation | Tumor weight [g] | 2.570 | 0.680 | 3.190 | 1.120 | ↙ |
| 19 | Zhu et al. ( | 60 | 60 | Female Sprague-Dawley rats (20 days) | Intraperitoneal administration of 50 mg/kg body weight of 1-methyl 1-nitrosourea (MNU) | Voluntary wheel running | N.A. | 7 days after inoculation for 8 weeks | Tumor weight [mg] per animal [g] | 0.620 | 0.140 | 1.160 | 0.210 | ↓ |
| 441 | 477 | |||||||||||||
| Total number subjects | 918 | |||||||||||||
Summary of studies that displayed tumor size in tumor weight. n, number of subjects; Ex, exercise group; C, sedentary control group; d, day(s);weeks, week(s); M, Mean; S.E.M, standard error of the mean; No. , Number; ?, slight increase in tumor size; ?, slight decrease in tumor size; ↑, increase in tumor size; ↓, decrease in tumor size.
Figure 4Meta-analysis of tumor software output presenting Hedges's g, 95% CI (confidence interval) and p-value of the random effect model of tumor size. The size of the squares and the thickness of the horizontal lines express the weight of the presented study. The total Hedges' g effect size is presented as green diamond. Its width expresses the CI. The vertical line at zero represents no difference in adjusted effect size of exercise on tumor growth. Data on the left from the line stands for a decrease and data on the right stands for an increase of tumor size. The heterogeneity was calculated and was shown to be at the end range of moderate [I2 = 70.28%; Q = 60.57; df(Q) = 18; p < 0.00].
Figure 5Adjusted effect sizes of the investigated groups tested by the predefined moderators, k, number of studies in the subgroup; I2, measure of heterogeneity.
Moderator congregated by different covariates.
| Outcome measure | Tumor volume [mm3] | 4 | 4.74 | 2 | 0.094 | 8 |
| Tumor weight in [g] | 10 | |||||
| Tumor weight [mg] per animal [g] | 3 | |||||
| Combined measurement | 2 | |||||
| Measure | Weight | 13 | 1.49 | 1 | 0.2219 | 0 |
| Seize | 4 | |||||
| Combined measurement | 2 | |||||
| Type of rodent | Mice | 7 | 0.08 | 1 | 0.7730 | 0 |
| Rats | 12 | |||||
| Type of cancer | Breast cancer | 13 | 3.26 | 3 | 0.354 | 0 |
| Liver cancer | 2 | |||||
| Lung cancer | 3 | |||||
| Prostate cancer | 1 | |||||
| Training initiation | After inoculation | 10 | 7.12 | 2 | 0.0284* | 27 |
| Before inoculation | 1 | |||||
| Before and after inoculation | 8 | |||||
| Exercise period | < 10 weeks | 14 | 0.67 | 1 | 0.4132 | 0 |
| >10 weeks | 5 | |||||
| Type of exercise | Swimming | 6 | 5.44 | 2 | 0.0659* | 17 |
| Treadmill running | 9 | |||||
| Voluntary wheel running | 4 | |||||
| Maximum daily exercise | < 60 min | 8 | 9.41 | 2 | 0.0091* | 33 |
| 60 min+ | 7 | |||||
| Voluntary exercise time | 4 | |||||
| Gender | Female | 9 | 2.42 | 1 | 0.120 | 6 |
| Male | 10 | |||||
| Type of cancer administration | Intraperitoneal | 6 | 8.85 | 3 | 0.031* | 28 |
| Intravenous | 1 | |||||
| Spontaneous | 1 | |||||
| Subcutaneous | 11 | |||||
| Age | 0–25 days of age | 8 | 3.95 | 2 | 0.1388 | 20 |
| 25–50 days of age | 5 | |||||
| >50 days of age | 6 | |||||
*P < 0.05.